252932-49-3

Usage

Chemical Properties

White solid

InChI:InChI=1/C7H10N2O2.ClH/c1-2-11-7(10)6-5(8)3-4-9-6;/h3-4,9H,2,8H2,1H3;1H

Upstream product

• 1021175-71-2 diethyl 2-(2-cyanovinylamino)malonate 
• 252932-48-2 3-amino-2-ethoxycarbonylpyrrole 

Downstream Products

• 252932-48-2 3-amino-2-ethoxycarbonylpyrrole 
• 890656-26-5 ethyl 3-amino-4-bromo-1H-pyrrole-2-carboxylate 
• 959850-72-7 1-[2-(benzyloxy)ethyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 
• 939979-34-7 ethyl 3-ureido-1H-pyrrole-2-carboxylate 
• 65996-50-1 2,4-Dioxo-1,2,3,4-tetrahydropyrrolo<3,2-d>pyrimidine 
• 5655-01-6 3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one 
• 5655-01-6 9-deazahypoxanthine 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF VERDIPERSTAT

An improved process for preparing verdiperstat is disclosed. The process includes the steps of reacting a compound having formula or a salt thereof, wherein R is the same or different and is each independently a C1-C5 alkyl with 3-(dimethylamino)acrylonitrile to obtain a compound having formula; and converting the compound having formula to verdiperstat.

Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives

Here, we describe the design and synthesis of two series of 4-pyrrylamino quinazolines as new analogs of the epidermal growth factor receptor inhibitor gefitinib. In vitro antitumor activity of these novel compounds against pancreatic (Miapaca2) and prostate (DU145) cancer cell lines was evaluated. Compared with the parental gefitinib, all 18 derivatives show a greatly increased cytotoxicity to cancer cells. In vitro kinase inhibitory activity on epidermal growth factor receptor was also investigated. Among them, compounds GI-6, GII-4, GII-6, GII-8, and GII-9 are more potential receptor tyrosine kinase (RTK) inhibitors. Based on these results, we propose simple structure-activity relationship to provide information for designing and developing more potent antitumor agents.

Process for preparing 2-pyrrolidinyl-1H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism

A process of preparing a compound of the formula (I) wherein B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and Z is selected from OH, hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted all, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof, which comprises reacting a compound of the formula (II) ?with an anion produced by abstraction of the bromine or iodine atom from a compound of formula (XIX), ?to form a compound of formula (XX) The compound of formula (XX) is N- and O-deprotected to obtain the compound of formula (I).